Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Denton

Showing results (161-170 of 484) with videos related to

Pageof 49
Sort By:
Clinical Rheumatology|September 5, 2019
Optimisation of botulinum toxin type a treatment for the management of Raynaud's phenomenon using a dorsal approach: a prospective case seriesKiran Dhaliwal, Michelle F Griffin, Sebastian Salinas, et al.
Rheumatology (Oxford, England)|August 24, 2020
High proton pump inhibitor exposure increases risk of calcinosis in systemic sclerosisLauren V Host, Corrado Campochiaro, Ana Afonso, et al.
Clinical and Experimental Rheumatology|June 14, 2012
Role of N-terminal pro-brain natriuretic peptide in detecting clinically significant cardiac involvement in systemic sclerosis patientsCecilia Chighizola, Pier Luigi Meroni, Benjamin E Schreiber, et al.
JAMA Dermatology|May 26, 2021
A Practical Approach to the Management of Digital Ulcers in Patients With Systemic Sclerosis: A Narrative ReviewMichael Hughes, Yannick Allanore, Khadija El Aoufy, et al.
The Journal of Rheumatology|April 15, 2025
Outcomes in Systemic Sclerosis-Associated Interstitial Lung Disease Based on Serological Profiles With a Focus on Anticentromere and Anti-RNA Polymerase III AntibodiesElizabeth R Volkmann, Shervin Assassi, Christopher P Denton, et al.
Respiratory Medicine|August 6, 2016
Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trialAryeh Fischer, Christopher P Denton, Marco Matucci-Cerinic, et al.
Rheumatology (Oxford, England)|April 28, 2021
Autoantibody predictors of gastrointestinal symptoms in systemic sclerosisFiza Ahmed, Rory H Maclean, Svetlana I Nihtyanova, et al.
Annals of the Rheumatic Diseases|May 16, 2012
Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosisKorsa Khan, Shiwen Xu, Svetlana Nihtyanova, et al.
Rheumatology (Oxford, England)|July 21, 2022
Macrophages as determinants and regulators of fibrosis in systemic sclerosisYehya Al-Adwi, Johanna Westra, Harry van Goor, et al.
Rheumatology (Oxford, England)|August 3, 2010
Clinical experience with bosentan and sitaxentan in connective tissue disease-associated pulmonary arterial hypertensionChristopher J Valerio, Clive E Handler, Peter Kabunga, et al.
Pageof 49

Showing results (161-170 of 484) with videos related to

Sort By:
Pageof 49
Clinical Rheumatology|September 5, 2019
Optimisation of botulinum toxin type a treatment for the management of Raynaud's phenomenon using a dorsal approach: a prospective case seriesKiran Dhaliwal, Michelle F Griffin, Sebastian Salinas, et al.
Rheumatology (Oxford, England)|August 24, 2020
High proton pump inhibitor exposure increases risk of calcinosis in systemic sclerosisLauren V Host, Corrado Campochiaro, Ana Afonso, et al.
Clinical and Experimental Rheumatology|June 14, 2012
Role of N-terminal pro-brain natriuretic peptide in detecting clinically significant cardiac involvement in systemic sclerosis patientsCecilia Chighizola, Pier Luigi Meroni, Benjamin E Schreiber, et al.
JAMA Dermatology|May 26, 2021
A Practical Approach to the Management of Digital Ulcers in Patients With Systemic Sclerosis: A Narrative ReviewMichael Hughes, Yannick Allanore, Khadija El Aoufy, et al.
The Journal of Rheumatology|April 15, 2025
Outcomes in Systemic Sclerosis-Associated Interstitial Lung Disease Based on Serological Profiles With a Focus on Anticentromere and Anti-RNA Polymerase III AntibodiesElizabeth R Volkmann, Shervin Assassi, Christopher P Denton, et al.
Respiratory Medicine|August 6, 2016
Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trialAryeh Fischer, Christopher P Denton, Marco Matucci-Cerinic, et al.
Rheumatology (Oxford, England)|April 28, 2021
Autoantibody predictors of gastrointestinal symptoms in systemic sclerosisFiza Ahmed, Rory H Maclean, Svetlana I Nihtyanova, et al.
Annals of the Rheumatic Diseases|May 16, 2012
Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosisKorsa Khan, Shiwen Xu, Svetlana Nihtyanova, et al.
Rheumatology (Oxford, England)|July 21, 2022
Macrophages as determinants and regulators of fibrosis in systemic sclerosisYehya Al-Adwi, Johanna Westra, Harry van Goor, et al.
Rheumatology (Oxford, England)|August 3, 2010
Clinical experience with bosentan and sitaxentan in connective tissue disease-associated pulmonary arterial hypertensionChristopher J Valerio, Clive E Handler, Peter Kabunga, et al.
Pageof 49